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Abstract
Background: The objective of this study is to describe variations in the healthcare resource utilization (HRU) among
individuals with Angelman syndrome (AS) over the first 12 years of life. Data for this study were drawn from the AS
Natural History study (ASNHS), which is an observational study on the developmental progress, behavior, and
medical morbidity of individuals with AS conducted over eight years. Caregiver-reported information on
hospitalization, surgery, and medication utilization was used to assess HRU. Repeated measures mixed effect models
were used to assess the relationship between age and probability of hospitalization, surgery, and prescription
medication utilization.
Results: Mean age at study enrollment was 6 years of age and both sexes were equally represented. The mean
number of visits per participant was three. Results from this study suggest that individuals with AS have a high HRU
burden. Hospitalization and surgery burden were highest in the first year of life. Use of medications for seizures and
sleep disturbance increased over time.
Conclusions: The study highlights the significant healthcare burden among individuals with AS. Future studies that
estimate cost and caregiver burden associated with AS are needed to assess the lifelong economic impact of AS on
families and healthcare system.
Keywords: Healthcare economics, Healthcare resource utilization, Rare disease, Disease burden
Background
Angelman syndrome (AS) is a rare, neurodevelopmental
condition characterized by severe impairment in behav-
ior, motor function, sleep, and cognition. There are no
approved treatments for AS and the current goal is man-
agement of comorbidities and symptoms [1]. AS has an
impact on overall health, severely limiting activities of
daily living and individuals require lifelong support from
a network of specialists and caregivers.
There is limited information on the healthcare burden
of individuals with AS and how it varies with age. In a
study of 34 individuals with a mean age of 21.6 years, [2]
Thomson et al. found that individuals with AS had a high
hospitalization burden (median of 5.5 hospitalizations per
person) and the most common reasons for hospitalization
were seizures, gastrointestinal disorders, and dental work.
Another study found that the most common reasons for
hospitalization were dental care, seizures, orthopedic
problems, and acute respiratory disorders [3]. Our previ-
ous analysis using data from baseline visits of the AS Nat-
ural History Study (ASNHS) found that more than 60% of
individuals had a history of at least one hospitalization
from birth to enrollment into the study [4]. The most
common reasons for hospitalizations were seizures, lower
respiratory infections, and surgery. The most commonly
used medications were those for treatment of seizures,
gastroesophageal reflux disease, sleep, and behavioral dis-
orders. In addition, our study showed that individuals with
AS had high utilization of supportive therapies, such as
early childhood intervention and physical, occupational,
and speech therapies to promote development.
While the above studies have established the significant
healthcare burden for individuals with AS, there are no
published data on how this burden changes with age. The
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primary aim of this study is to describe how healthcare re-
source utilization (HRU) varies with age in the pediatric
population with AS in the United States (US). By docu-
menting the HRU among children with AS, we will begin
to characterize the unmet needs for this population, which
may help determine how resources should be allocated for
the management of this chronic condition.
Methods
Data
The ASNHS gathered longitudinal data on the developmen-
tal progress, behavior, and medical morbidity of individuals
with AS from 2006 to 2014 [5]. The study was conducted by
the Angelman, Rett, and Prader-Willi Syndromes Consor-
tium of the NIH Rare Diseases Clinical Research Network
(ClinicalTrials.gov Identifier: NCT00296764). Individuals
with AS were recruited at six study sites across the United
States. Inclusion criteria included a molecular or clinical
diagnosis of AS, and age between 1 day and 60 years. A total
of 311 individuals were enrolled in the ASNHS. For the pur-
pose of this analysis, only 302 individuals with molecularly
confirmed AS and no concomitant medical condition (simi-
lar intellectual disability) were included.
At the baseline visit and at each annual follow-up
visit, data were collected through interviews with the
caregiver who was present at the visit about the par-
ticipant’s previous and current medical history and
developmental progress since birth. With respect to
HRU, the dates of, and indications for, any
hospitalization or surgery, and length of stay (LOS)
were recorded. Information was also collected on the
use of prescription and non-prescription medications,
including the reasons for using each medication and
the duration of use.
The date of event (e.g., hospitalization) and date of
birth were used to calculate the age at time of event, if
age was not directly reported. If the event date was com-
pletely missing, the date of visit at which the event was
reported was used to calculate the age at time of event,
provided that no more than one annually scheduled visit
was missing immediately prior to the visit reporting the
event. If there was more than one missing annual visit
immediately prior to the visit reporting the event, then
age at time of event was considered missing and not in-
cluded in the analysis. As we could not determine
whether a given surgery was performed in an outpatient
or inpatient setting, hospitalization and surgery data
were not considered mutually exclusive. In addition,
length of stay (LOS) was defined as the number of nights
in a hospital, with a minimum of one overnight stay in
the hospital. Finally, analyses were restricted to individ-
uals 12 years of age or younger due to small sample sizes
for older age groups.
Statistical analysis
Descriptive statistics of the resource utilization in the
sample are presented by age. For continuous variables,
the mean and standard deviation (SD) are presented. For
categorical variables, frequencies and related percentages
are presented. To analyze how healthcare utilization
changes with age, a mixed model for repeated binary
measurements was used. Separate models were fitted to
estimate the probability of hospitalization, surgery, and
prescription medication utilization. Models included
fixed effects for intercept, age, molecular genotype, and
genotype-by-age interaction, and random effects for
intercept and slope. Molecular genotype was defined as
a binary measure where individuals with a deletion
genotype were categorized together and individuals with
non-deletion etiology were categorized otherwise, as the
reference category. Molecular etiology was added as a
covariate since previous studies suggested that individ-
uals with deletion genotype generally have a more severe
course [5–9]. All statistical analyses were performed
using SAS® Version 9.4 or higher for Windows.
Results
Table 1 shows basic demographic information and avail-
able data at the time of enrollment. Mean age at AS diag-
nosis was two years and 48% were male. Most of the
participants (62%) were less than five years old at the time of
enrollment. On average, individuals had approximately three
annual visits, including the baseline visit during which histor-
ical data were collected. Figure 1 shows the number of
Table 1 Baseline descriptive data and data availability in this
study
Variable N = 302
Age at diagnosis, years (mean, SD) 2 (3)
Male (n, %) 145 (48%)
Age at baseline, years (mean) 5.5 (5.9)
0–1 year (n, %) 53 (18%)
2 years (n, %) 61 (20%)
3 years (n, %) 37 (12%)
4 years (n, %) 35 (12%)
5 years (n, %) 20 (7%)
6 years (n, %) 11 (4%)
7 years (n, %) 8 (3%)
8 years (n, %) 11 (4%)
9 years (n, %) 14 (5%)
10 years (n, %) 9 (3%)
11 years (n, %) 7 (2%)
12 years (n, %) 9 (3%)
> 13 years (n, %) 25 (8%)
Number of visits, (mean, min-max) 3.3 (1–9)
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participants with the stated total number of visits. Approxi-
mately, 75% of individuals had at least two visits, 55% had at
least three or more visits, and 37% had four or more visits.
Table 2 presents descriptive statistics on HRU by age.
The occurrence of hospitalization was highest at 43% at
age one year or younger, decreased over time, and was
only 11% at age 12 years. There was a slight decrease
(27%) in the mean number of hospitalizations over time
from 1.5 hospitalizations by age one to 1.1 hospitaliza-
tions at age 12 years. Among those hospitalized, mean
LOS was 6.5 days at age one year (SD: 8.9), 3.6 days (SD:
5.8) at six years and 1.5 days (SD: 0.71) at 12 years. Sei-
zures and lower respiratory infection were the most
common reason for hospitalization. Similarly, surgeries
were more common in the younger patients: 29%, 9%,
and 5% at age one year, six years, and 12 years, respect-
ively. Tympanostomy tube insertion, strabismus correc-
tion, and tonsillectomy and adenoidectomy were the
most frequent surgeries in this sample and were more
common in infancy. Majority of individuals used one or
more prescription medications and utilization increased
with age (51% by age one year to 83% at age 9 years),
after which a slight decline was observed. The mean
number of prescription medication utilization increased
by 26% between age one year and age 12 years, with the
increase being non-linear. Use of anticonvulsant medica-
tions increased from 32% at age one year to 73% at age
seven years and stabilized thereafter. Use of medications
to treat GERD decreased from 27% at age one year to
13% at age six years and stabilized thereafter. Notably,
there was an increase in the number of individuals using
medications for behavioral and mental health indications,
which increased from 1% in the younger years to 23% at
age 12 years. Similarly, there was an increase in the number
of individuals using non-prescription sleep medications:
18% by the first year of life, 37% at age five years, and 23%
at age 12 years.
Table 3 presents estimates from repeated measure
mixed effect models for the probability of hospitalization,
surgery, and medication use. Results from these models
are consistent with the descriptive information presented
in Table 2. Estimates of the effect of age indicate that the
odds of hospitalization or surgery decreased with increas-
ing age. In contrast, based on the model, an increase in
age was associated with an increase in the odds of pre-
scription drug utilization in our sample. Specifically, the
model suggests that the probability of hospitalization at
age one year among those without a deletion was 0.20,
and 0.05 at age 12 years. In contrast, the probability of use
of prescription medication among those without deletion
was 0.14 at age one year and 0.99 at age 12 years, and
among those with a deletion, it was 0.54 and 0.99 at age
one year and 12 years respectively.
Discussion
AS is a rare condition with an estimated prevalence of 1
in 12,000 to 1 in 20,000 in the US [10]. The most consist-
ent features are global developmental delay marked by in-
tellectual disability, seizures, severe speech impairment,
behavior problems, and sleep disturbance, but the presen-
tation and severity of symptoms varies among individuals
and changes with age [11–13]. To the best of our know-
ledge, this is the first study to present the healthcare bur-
den associated with AS, from infancy to age 12 years.
The ASNHS is a large-scale longitudinal study of individ-
uals with AS in the US designed to improve knowledge of
the condition and investigate associated morbidity across
ages. Individuals in the analyzable sample were younger
than 12 years with a mean age of six years and equal sex
distribution. On average, we had three years of data for
each individual. Our analyses suggest an overall high HRU
in this population especially among younger children be-
tween 0 and 1 years of age. Hospitalization, surgeries and
use of prescription medications to manage various
Fig. 1 Number of individuals by number of visits, Notes: Number of participants with the stated total number of visits; participants who only had
the baseline visit had “1 visit”. Follow-up visits occurred approximately annually for participants
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symptoms were common. Our data suggests that younger
children, often in the first year of life, tended to experience
more surgeries, hospitalizations, and longer hospital stays
than older children. The use of prescription medications in-
creased with age in this cohort and by age six almost 80%
of children were using at least one medication.
Our analyses support the heterogeneity of the condition.
It appears that the various symptoms were managed
through a combination of hospital-based interventions
and prescription medications. Seizures are one of the most
common symptoms associated with AS [11], and antiepi-
leptic drugs (AEDs) are the accepted first-line treatment
for managing seizures in these individuals. In this study,
we found that AEDs were the most commonly used class
of medication, regardless of age, consistent with the high
incidence of seizures in this population.
Medications to treat sleep disturbance were the other
common category. Sleep difficulties may manifest as in-
creased sleep latency, decreased total sleep time, abnormal
sleep-wake cycle, and frequent nocturnal awakening [11].
Some studies suggest that sleep disturbances are more
common among young children 2 to 9 years of age and
improve with age, while others report that they continue
into adolescence and adulthood [1]. We found that use of
sleep medications increased with age. Use of melatonin, a
commonly used non-prescription medication, was 18% in
the first year, peaked at age 8 (34%) and continued to be
high into early adolescence (23 to 34%).
Table 2 Healthcare utilization among individuals with AS by age
Descriptive 0–1 2 3 4 5 6 7 8 9 10 11 12
N1 301 282 260 234 208 179 155 134 114 92 77 65
Hospitalization summary measures
Had hospitalization, % 43 24 21 18 14 13 13 10 12 7 8 11
Hospitalization per year, mean 1.5 1.3 1.3 1.6 1.4 1.1 1.1 1.2 1.4 1.2 1.3 1.1
LOS, mean 6.5 3.1 2.5 2.6 4.7 3.6 3.1 2.7 2.9 1 3.4 1.5
Most common reasons for hospitalization
Seizures, % 10 11 10 6 7 5 5 4 3 0 3 1
Lower respiratory infection, % 10 5 1 3 1 1 1 2 3 1 0 0
Surgery, % 5 3 2 2 1 0 1 2 0 0 0 0
Surgery summary measure
Had surgery, % 29 21 15 17 9 9 14 8 9 4 8 5
Most common reasons for surgery
Tympanostomy tubes, % 10 5 5 3 4 1 2 0 2 0 1 0
Strabismus, % 7 9 2 3 1 2 2 1 1 0 0 0
Tonsillectomy & adenoidectomy, % 2 2 5 5 2 2 1 0 1 0 0 0
Medication summary measures
Number of prescription medications, mean 2.1 2.0 2.1 2.3 2.3 2.1 2.2 2.2 2.3 2.5 2.5 2.7
At least one prescription medication, % 51 59 69 71 76 78 81 81 83 77 78 77
Anti-epileptic drugs, % 32 50 61 64 67 69 73 71 72 71 70 69
Anti-gastroesophageal reflux medication, % 27 15 12 13 12 13 11 12 13 10 12 9
Asthma and Allergy medication, % 5 5 7 9 7 6 7 7 8 5 4 6
Antibiotic, % 3 1 4 2 1 1 2 1 1 2 0 2
Sleep medication, % 3 6 9 12 15 18 17 19 18 16 20 26
Psychotropic medication, % 1 1 2 6 9 9 13 15 17 22 20 23
Other, % 2 1 6 5 6 5 8 6 5 7 10 11
Number of non-prescription medications, mean 1.6 1.9 1.8 1.9 1.9 2.0 2.0 2.1 2.1 2.2 2.1 1.8
Asthma and Allergy, % 3 5 5 6 7 7 8 5 5 5 7 8
Laxative, % 11 14 15 15 14 14 18 19 17 19 16 19
Sleep medication, % 18 30 31 35 37 33 33 34 31 29 25 23
Notes: 1Age is rounded down to the nearest year. The event counts for each age are based on the participants reported age at a specific event. Participant are
included in the overall N (denominator) for each age group until their age at last visit (the oldest age recorded). Participants are only counted once per age. For
ages 0–1 Year, the sum of the number of unique prescription/non-prescription medications taken at age 0 and at age 1 is summarized
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Individuals with AS may have behavioral issues, such as
hyperactivity, impulsivity, and aggressive behaviors [11].
We observed increasing use of behavioral/psychiatric (psy-
chotropic) medications with age. Use of medication to
treat GERD was highest in the first year of life, after which
use decreased, mirroring the typical age when this issue is
most problematic.
This study has several limitations. The population was
skewed towards individuals younger than five years old
and the mean number of data points per individual was
only three. The ASNHS study did not record any infor-
mation on use of outpatient care (e.g., visits to primary
care physicians, neurologists, geneticists, psychiatrists,
and other specialists). While not as costly as
hospitalization, outpatient care tends to be one of the
largest volume drivers of healthcare burden. We were
unable to determine whether the reported surgeries were
performed in an outpatient or an inpatient setting. Since
the data used in these analyses were collected via care-
giver (either primary or informal) interviews, the HRU
was likely underreported due to recall failure and should
be considered a minimum estimate, particularly true for
medication use. In addition, we are using the event dates
to create longitudinal history of healthcare utilization
and misreporting is likely to be higher for medication
use and as such the medication results should be inter-
preted in the light of these limitations. Replication of the
findings in this study using claims data or administrative
sources will help to corroborate these results.
Conclusions
In summary, this is the first study to describe how the
HRU varies with age in children with AS. We have
shown overall high HRU use as well as different types of
HRU, to manage a constellation of heterogeneous symp-
toms and co-morbidities. The high healthcare burden
for these individuals and their families can be demon-
strated by the high hospitalization and surgery rates, es-
pecially in the first year of life. We also described how
the use of medications increased with age, especially for
conditions such as seizures, sleep disturbance, and be-
havioral issues. Future studies are required to provide a
holistic view on the HRU use in both children and adults
and evaluate the overall impact on caregivers and the
healthcare system.
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